| Literature DB >> 28911407 |
Mohamed El-Shazly1,2, Chi-Jung Tai1,3, Tung-Ying Wu4, Dezső Csupor5, Judit Hohmann5, Fang-Rong Chang1,6,7,8, Yang-Chang Wu1,9,4,10.
Abstract
Aconitum and its products have been used in Asia for centuries to treat various ailments, including arthritis, gout, cancer, and inflammation. In general, their preparations and dispensing have been restricted to qualified folk medicine healers due to their low safety index and reported toxicity. In the past few decades, official guidelines have been introduced in Asian pharmacopeias to control Aconitum herbal products. However, these guidelines were based on primitive analytical techniques for the determination of the whole Aconitum alkaloids and were unable to distinguish between toxic and nontoxic components. Recent advances in analytical techniques, especially high performance liquid chromatography (HPLC) and electrophoresis coupled with highly sensitive detectors, allowed rapid and accurate determination of Aconitum secondary metabolites. Reports focusing on liquid chromatography/mass spectrometry analysis of Aconitum and its herbal products are discussed in the current review. This review can be used by the health regulatory authorities for updating pharmacopeial guidelines of Aconitum and its herbal products.Entities:
Keywords: Aconitum; Asia; arthritis; diterpene alkaloids; liquid chromatography/mass spectrometry
Year: 2015 PMID: 28911407 PMCID: PMC9345420 DOI: 10.1016/j.jfda.2015.09.001
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Representative sample preparation procedures for aconite roots and their products in recent publications.
| Analytes | Samples | Extraction procedures | Analysis | Refs |
|---|---|---|---|---|
|
| ||||
| BMA | P-AR & its proprietary products containing processed aconite roots | Extract P-AR with 50% EtOH (×3, 60 min each time) via sonication & alkaloids from unP-AR via general method. | HPLC-PDA | [ |
|
| ||||
| AC, MA, & HA | P-AR & unP-AR | Extract P-AR & unP-AR with 75% EtOH (×3, 30 min each time) via sonication. | HPLC-PDA | [ |
| AC, MA, & HA | Aconite roots & decoction pieces containing processed aconite roots | Extract with methanol–water (1:1, v/v) via sonication for60 min. | HPLC-PDA & HPLC–ESI–MS | [ |
| AC, MA, & HA | Aconite roots | Extract using the general extraction procedures. | HPLC-PDA | [ |
| AC, MA, & HA | Shen-Fu decoction (Radix ginseng & Fuzi at a ratio of 3:2) containing processed aconite roots | Extract with water under reflux (1:10 v/v, ×3, 60 min each time), & dissolve the corresponding residue in water. | RRLC–ESI–MS/MS | [ |
| AC, MA, & HA | Unprocessed aconite roots | Extract P-AR & unP-AR with chloroform (1:10 v/v, for 30 min) via sonication & dissolve the obtained residue in methanol. | UPLC–Q-TOF–MS | [ |
|
| ||||
| MDAs: BAC, BMA, & BHA | P-AR, unP-AR & proprietary Chinese medicines (pills, tablets, & capsules) containing processed aconite roots | Extract by alkaloidal extraction procedures. | HPLC-PDA | [ |
| MDAs: BAC, BMA, & BHA | Raw material & P-AR | Extract by alkaloidal extraction procedures. | HPLC-PDA & HPLC–ESI–MS/MS | [ |
| DDAs: AC, MA, & HA | P-AR & its proprietary products ( | Add ammonia TS (40% NH3·H2O) to each sample & extract with diethyl ether in an ultrasonic bath for 30 min, & dissolve the corresponding residue with methanol. To each sample of pills, add ammonia TS (40% NH3·H2O) & extract with isopropanol–ethyl acetate (1:1, v/v) in an ultrasonic bath for 30 min, & dissolve the corresponding residue in acetonitrile. | UPLC–ESI–MS | [ |
| MDAs: BAC, BMA, & BHA | P-AR, unP-AR, & its patent Chinese medicine products (pills) containing processed aconite roots | Extract with 50% methanol (containing 2.5% formic acid) by microwave for 1 min at a power level of 420 W. | UPLC–ESI–MS/MS | [ |
| MDAs: BAC, BMA, & BHA | Decoction & maceration of Fuzi Xiexin Tang containing P-AR | Extract with water under reflux (1:10 & 1:8 v/v, ×2, for 1 h or1.5 h) & dissolve the corresponding residue in water. Maceration of FXT: reflux the weighted sample of Radix Aconiti Lateralis Preparata with water (1:10 & 1:8 v/v, ×2, for 1 h or 1.5 h) & combine the corresponding decoction with another prepared maceration of Sanhuang Xiexin Tang to obtain MFXT. | UPLC–ESI–MS | [ |
|
| ||||
| Nonester type: higenamine | Fuzi decoction (Heishunpian & Baifupian) | Extract with water under reflux (1:10, v/v, ×3, for 60 min each time) & dissolve the corresponding residue in water. | RRLC–ESI–MS/MS | [ |
| Nonester type (aminoalcohol-diterpenoid alkaloids): beiwutinine; mesaconine; karakoline; isotalatizidine; aconine; 8-methoxymesaconine; hypaconine; fuziline; 3-deoxyaconine; neoline; 8-methoxyhypaconine; talatizamine; & chasmanine | 21 batches of Fuzi from different regions; all the samples were processed from the lateral roots of | Extract by alkaloidal extraction procedures | HPLC–ESI–MS/MS | [ |
| Nonester type: songorine; fuziline; neoline; talatisamine; guanfubase H | Shen-Fu injection prepared from red ginseng & processed aconite root | Prepare each sample in acetonitrile–water (1:1, v/v). | UPLC–Q-TOF–MS | [ |
AC = aconitine; BAC = benzoylaconine; BHA = benzoylhypaconine; BMA = benzoylmesaconine; DDA = diester-diterpenoid alkaloid; ESI = electrospray ionization; HA = hypaconitine; HPLC = high-performance liquid chromatography; MA = mesaconitine; MDA = monoester-diterpenoid alkaloid; MFXT = maceration of Fuzi Xiexin Tang; MS = mass spectrometry; MS/MS = tandem mass spectrometry; MSXT = maceration of Fuzi Xiexin Tang; P-AR = processed aconite root; Q-TOF = quadrupole time of flight; RRLC = rapid resolution liquid chromatography; TOF = time of flight; unP-AR = unprocessed aconite root; UPLC = ultra-performance liquid chromatography; YA = yunaconitine; PDA = Photodiode Array Detector; ACN = acetonitrile; TEA = triethylamine; EtOH = ethanol.
Alkaloid extraction procedure: each sample was dissolved/extracted in HCl/ammonia solution by sonication, and further extracted with ethyl acetate/ethyl ether to remove nonalkaloid components. The acidic/basic aqueous solution was basified/acidified with ammonia/HCl solution to adjust the pH value, and extracted with chloroform/ethyl ether to obtain the alkaloid components.
Analytical methods of aconite roots and their proprietary products.
| Method | Analytes | Samples | Details | Refs |
|---|---|---|---|---|
|
| ||||
| HPLC-PDA | BMA | P-AR; proprietary products containing processed aconite roots | Alltima RP-C18 (250 × 4.6 mm, 5 μm) was used with the Alltima RP-C18 guard column (7.5 × 4.6 mm) at room temperature. Elution of the alkaloids was carried out using a gradient system of acetonitrile & buffer solution at a flow rate of 1.0 mL/min, detected at 240 nm, validated with linearity, LOD, precision, repeatability, & recovery. | [ |
|
| ||||
| HPLC-PDA | AC, MA, & HA | P-AR & unP-AR | Waters Xterra RP18 column (250 × 4.6 mm, 5 μm) was used with the Xterra RP18 guard column (20 × 3.9 mm) at room temperature. Elution of the alkaloids was carried out using a gradient system of acetonitrile & 10 mM ammonium bicarbonate buffer solution at a flow rate of 1.0 mL/min, detected at 240 nm, validated with linearity, LOD, precision, repeatability, & recovery. | [ |
| HPLC-PDA & HPLC–ESI/MS | AC, MA, & HA | Aconite roots & decoction pieces containing processed aconite roots | Waters Xterra RP18 column (250 × 4.6 mm, 5 μm) was used & column temperature maintained at 25 °C. Mobile phase was carried out using a gradient system of 2.5 mM ammonium bicarbonate in water at pH 10 & acetonitrile at a flow rate of 1.0 mL/min, detected at 240 nm & positive ion mode for ESI/MS, validated with linearity, LOD, LOQ, precision, repeatability, & recovery. | [ |
| HPLC-PDA | AC, MA, & HA | Aconite roots | Phenomenex Luna C18 column (250 × 4.6 mm, 5 μm) was used & column temperature maintained at room temperature. Mobile phase was carried out using a gradient system of acetonitrile & ammonium bicarbonate buffer solution at a flow rate of 1.0 mL/min, detected at 231 nm, validated with linearity, LOD, LOQ, precision, repeatability, & recovery. | [ |
| RRLC–ESI/MS/MS | AC, MA, & HA | Shen-Fu decoction (Radix Ginseng & Fuzi at a ratio of 3:2) containing processed aconite roots | Agilent ZORBAXC18 SB column (100 mm × 2.1 mm, 1.8 μm) was used & column temperature maintained at 40 °C. The gradient mobile phases consisted of water containing 0.05% formic acid & acetonitrile at a flow rate of 0.35 mL/min. The positive ion mode for ESI/MS/MS (totally 10 major components identified, 3 DDAs from Fuzi) was validated & quantitatively analyzed. | [ |
| UPLC–Q-TOF–MS | AC, MA, & HA | unP-AR | Separation of components in the samples was performed at 20 °C, using a Waters UPLC C18 analytical column (100 mm × 2.1 mm, 1.7 μm) attached with a C18 precolumn (2.1 mm × 5 mm, 1.7 μm). The gradient mobile phase consisted of a mixture of water & acetonitrile, both containing 0.1% formic acid at a flow rate of 0.4 mL/min. The three analytes of unprocessed aconite roots & the corresponding detoxification process samples were validated & qualified using the UHPLC–Q-TOF–MS in positive ion mode. | [ |
|
| ||||
| HPLC-PDA | MDAs: BAC, BMA, & BHA | P-AR, unP-AR, & proprietary Chinese medicines (pills, tablets, & capsules) containing processed aconite roots | Alltima RP-C18 (250 × 4.6 mm, 5 μm) was used as the stationary phase accompanied by Alltima RP-C18 guard column (7.5 × 4.6 mm) at room temperature. Elution of the six alkaloids was carried out using a gradient system of acetonitrile & buffer solution at a flow rate of 1.0 mL/min, detected at 240 nm, validated with linearity, LOD, precision, repeatability, & recovery. | [ |
| HPLC-PDA & HPLC–ESI/MS/MS | MDAs: BAC, BMA, & BHA | Raw material & P-AR | Microsorb C18 column (250 × 4.6 mm, 5 μm) was used with an Econosphere C18 guard column, & column temperature maintained at 45 °C. Mobile phase was carried out using a gradient system of ACN, TEA buffer & THF at a flow rate of 1.0 mL/min, detected at 238 nm, validated with linearity, LOD, LOQ, precision, repeatability, & recovery, & detected & quantified with ESI/MS/MS spectra in positive ion mode. | [ |
| UPLC–ESI–MS | MDAs: BAC, BMA, & BHA | P-AR & its proprietary products ( | Agilent ZORBAXC18 SB column (100 mm × 2.1 mm, 1.8 μm) was used & column temperature maintained at 35 °C. Mobile phase was carried out using a gradient system of 0.1% aqueous formic acid & acetonitrile (65:35, v/v) at a flow rate of 0.3 mL/min. Quantification analysis was achieved on ESI/MS in positive ionmode & SIR mode, validated, & quantitatively analyzed. | [ |
| UPLC–ESI–MS/MS | MDAs: BAC, BMA, & BHA | P-AR, unP-AR & its patent Chinese medicine products (pills) containing processed aconite roots | Waters Acquity UPLC BEHC18 column (100 mm × 2.1 mm, 1.7 μm) was used for chromatographic separation & column temperature maintained at 40 °C. The gradient mobile phase consisted of a mixture of 0.1% formic acid aqueous solution & methanol-1,4-dioxane (80:20, containing 0.1% formic acid) at a flow rate of 0.6 mL/min. Quantification analysis was achieved using ESI/MS/MS in positive ion mode & MRM mode, validated, & quantitatively analyzed. | [ |
| UPLC–ESI–MS | MDAs: BAC, BMA, & BHA | Decoction & maceration of Fuzi Xiexin Tang containing processed aconite roots | Waters Acquity UPLC BEHC18 column (50 mm × 2.1 mm, 1.7 μm) was used for the chromatographic separation & column temperature maintained at 45 °C. The gradient mobile phase consisted of 0.1% formic acid aqueous solution & acetonitrile at a flow rate of 0.3 mL/min. Quantification analysis was achieved on ESI/MS in positive ion mode & SIR mode, validated, & quantitatively analyzed. | [ |
|
| ||||
| RRLC–ESI–MS/MS | Nonester type: higenamine | Fuzi decoction (Heishunpian & Baifupian) | The separation was carried out on an Agilent ZORBAXC18 SB column (100 × 2.1 mm, 1.8 μm) & column temperature maintained at 40 °C. The gradient mobile phase consisted of 0.1% formic acid aqueous solution & acetonitrile at a flow rate of 0.35 mL/min. Quantification analysis was achieved using ESI/MS/MS in positive ion mode & MRM mode, validated, & quantitatively analyzed. | [ |
| HPLC–ESI–MS/MS | Nonester type (aminoalcohol-diterpenoid alkaloids): beiwutinine; mesaconine; karakoline; isotalatizidine; aconine; 8-methoxymesaconine; hypaconine; fuziline; 3-deoxyaconine; neoline; 8-methoxyhypaconine; talatizamine; & chasmanine | 21 batches of Fuzi from different regions; all the samples were processed from the lateral roots of | Chromatographic separations the thirteen alkaloids were performed on a Hypersil ODS2 column (4.6 mm × 150 mm, 5 μm), which was conjuncted with a SecurityGuard cartridge (Phenomenex) at ambient temperature. The isocratic mobile phase was composed of methanol-0.1% formic acid (80:20, v/v) at a flow rate of 1.0 mL/min. Quantification analysis was achieved using ESI/MS/MS in positive ion mode & MRM mode, validated & quantitatively analyzed. | [ |
| UPLC–Q-TOF–MS & HPLC–ESI/MS | Nonester type: songorine; fuziline; neoline; talatisamine; guanfubase H | Shen-Fu injection prepared from red ginseng & P-AR | Chromatographic separation for 11 alkaloids was performed on an Agilent Zorbax SB-C18 column (4.6 mm × 250 mm, 5 μm) at 30°C. The gradient mobile phase consisted of 10mM ammonium formate–water & 0.1% formic acid acetonitrile at a flow rate of 1.0 mL/min. Quantification analysis was achieved on ESI/MS in positive ion mode & selected ion monitoring mode, validated, & quantitatively analyzed. | [ |
AC = aconitine; BAC = benzoylaconine; BHA = benzoylhypaconine; BMA = benzoylmesaconine; DDA = diester-diterpenoid alkaloid; ESI = electrospray ionization; HA = hypaconitine; HPLC = high-performance liquid chromatography; LOD = limit of detection; LOQ = limit of quantification; MA = mesaconitine; MDA = monoester-diterpenoid alkaloid; MRM = multiple reaction monitoring; MS = mass spectrometry; MS/MS = tandem mass spectrometry; P-AR = processed aconite root; Q-TOF = quadrupole time of flight; RRLC = rapid resolution liquid chromatography; SIR = selected ion recording; TOF = time of flight; UHPLC = ultra-high-performance liquid chromatography; unP-AR = unprocessed aconite root; UPLC = ultra-performance liquid chromatography; YA = yunaconitine.